Autologous blood stem cell transplantation for haematological malignancy: treatment-related mortality of 2%

Australian and New Zealand Journal of Medicine
K AtkinsonJ Rutovitz

Abstract

Lengthy remission or cure has remained elusive for patients with many of the common haematological malignancies. Thus high dose chemotherapy followed by autologous haemopoietic stem cell transplantation is being increasingly utilised in these diseases. To assess the safety of high dose chemotherapy and autologous stem cell transplantation in haematological malignancy. Forty-eight patients with haematological malignancy were given high dose chemotherapy followed by an infusion of previously cryopreserved autologous peripheral blood stem cells with (patients with acute myeloid leukaemia [AML]) or without (patients with acute lymphoblastic leukaemia [ALL], chronic myeloid leukaemia, non-Hodgkin's lymphoma, Hodgkin's disease and myeloma) autologous bone marrow. All patients except one had sustained engraftment. The median (range) number of days to attain a neutrophil count of 0.5 x 10(9)/L was 12 (10-42) and a platelet count of 20 x 10(9)/L unsupported by platelet transfusions was 15 (eight to 155). Other than oropharyngeal mucositis and febrile neutropenia, morbidity was low. Two patients had haemorrhagic cystitis, one hepatic veno-occlusive disease and one interstitial pneumonitis; all resolved. The treatment-related mortality wa...Continue Reading

References

Feb 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B LöwenbergR Goudsmit
Jun 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P ValagussaG Bonadonna
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G B McDonaldE D Thomas
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H C SchoutenA H Goldstone
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S FreedmanM J Robertson
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P PetersE Shpall

❮ Previous
Next ❯

Citations

Jul 18, 2001·Springer Seminars in Immunopathology·J Moore, P Brooks
Aug 1, 1997·Seminars in Oncology Nursing·L H Yoder
Jan 29, 2002·Best Practice & Research. Clinical Rheumatology·J MooreP Brooks
Jul 1, 1997·The Hastings Center Report·C E Schneider

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.